⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911551 | 0.95 | — | — | |
| SCHEMBL13559951 | 0.78 | — | — | |
| SCHEMBL13559953 | 0.78 | — | — | |
| SCHEMBL508798 | 0.74 | — | — | |
| SCHEMBL5055 | 0.68 | — | — | |
| SCHEMBL16187034 | 0.68 | — | — | |
| SCHEMBL1332459 | 0.68 | — | — | |
| SCHEMBL1332288 | 0.68 | — | — | |
| SCHEMBL12160498 | 0.68 | — | — | |
| SCHEMBL11656036 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325708-B2 | Adenosine 2 receptor antagonists | NEKTAR THERAPEUTICS (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250163026-A1 | Deuterium-Enriched Nirmatrelvir as SARS-CoV-2 Mpro Inhibitor for the Treatment of COVID-19 | DHANOA DALJIT SINGH (US) | 2025-05-22 | — | — | US | disclosed |
| EP-3603674-B1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF INTRACTABLE AND CHRONIC PAIN | SUN PHARMACEUTICAL IND INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS | 2022-07-28 | — | — | US | disclosed |
| US-20220023292-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | disclosed |
| WO-2020227156-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS (US) | 2020-11-12 | — | — | WO | disclosed |
| US-10813926-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3603674-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF INTRACTABLE AND CHRONIC PAIN | CONCERT PHARMACEUTICALS, INC. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10406155-B2 | Morphinan compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20120029007-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC. | 2012-02-02 | — | — | US | disclosed |
| EP-2397158-A2 | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110257214-A1 | MORPHINAN COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2011-10-20 | — | — | US | disclosed |
| EP-2365808-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | Concert Pharmaceuticals Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2334678-A1 | MORPHINAN COMPOUNDS | Concert Pharmaceuticals Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010062692-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010033801-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2004035517-A1 | SPECIFIC MARKERS OF LIPID PEROXIDATION | INSERM (FR) | 2004-04-29 | — | — | WO | disclosed |
| EP-1411041-A1 | Specific markers of lipid peroxidation | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2004-04-21 | — | — | EP | disclosed |